Advicenne SA
3MM
Company Profile
Business description
Advicenne SA is a late-stage biopharmaceutical company. The company is engaged in the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its goal is to improve the lives of patients from early childhood through adulthood.
Contact
262, rue du Faubourg Saint-Honor
Paris75008
FRAT: +33 185733620
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Why great earnings haven't been good enough for AI hardware stocks
Stocks that had been posting triple-digit returns are sliding on earnings results.
stocks
Fair Value increased for Big 4 bank after earnings
Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.
stocks
Chart of the Week: Why ASX tech is poised for a comeback
The “SaaSpocalypse” never arrived. Now, software stocks are positioning for a long-awaited comeback.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,381.40 | 9.10 | -0.10% |
| CAC 40 | 8,653.43 | 21.51 | -0.25% |
| DAX 40 | 26,318.77 | 12.30 | -0.05% |
| Dow JONES (US) | 53,730.99 | 39.28 | -0.07% |
| FTSE 100 | 10,759.24 | 73.91 | -0.68% |
| HKSE | 25,396.51 | 43.66 | -0.17% |
| NASDAQ | 26,805.23 | 216.75 | 0.82% |
| Nikkei 225 | 68,308.59 | 784.53 | 1.16% |
| NZX 50 Index | 13,825.30 | 87.64 | 0.64% |
| S&P 500 | 7,794.66 | 46.16 | 0.60% |
| S&P/ASX 200 | 9,188.50 | 4.40 | -0.05% |
| SSE Composite Index | 3,926.96 | 19.71 | -0.50% |